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Synopsis
Sirtuins are NAD+ -dependent protein deacetylases regulating metabolism, stress responses and ageing processes.
Among the seven mammalian Sirtuins, Sirt1 is the physiologically best-studied isoform. It regulates nuclear functions
such as chromatin remodelling and gene transcription, and it appears to mediate beneficial effects of a low calorie
diet which can partly be mimicked by the Sirt1 activating polyphenol resveratrol. The molecular details of Sirt1 domain
architecture and regulation, however, are little understood. It has a unique N-terminal domain and CTD (C-terminal
domain) flanking a conserved Sirtuin catalytic core and these extensions are assumed to mediate Sirt1-specific
features such as homo-oligomerization and activation by resveratrol. To analyse the architecture of human Sirt1 and
functions of its N- and C-terminal extensions, we recombinantly produced Sirt1 and Sirt1 deletion constructs as well as
the AROS (active regulator of Sirt1) protein. We then studied Sirt1 features such as molecular size, secondary structure
and stimulation by small molecules and AROS. We find that Sirt1 is monomeric and has extended conformations in
its flanking domains, likely disordered especially in the N-terminus, resulting in an increased hydrodynamic radius.
Nevertheless, both termini increase Sirt1 deacetylase activity, indicating a regulatory function. We also find an unusual
but defined conformation for AROS protein, which fails, however, to stimulate Sirt1. Resveratrol, in contrast, activates
the Sirt1 catalytic core independent of the terminal domains, indicating a binding site within the catalytic core and
suggesting that small molecule activators for other isoforms might also exist.
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INTRODUCTION
Sirtuins form an evolutionarily conserved family of protein
deacetylases [1]. In contrast with other deacetylase families, they
hydrolyse one NAD+ for each lysine residue they deacetylate,
rendering them metabolic sensors [2,3]. Sirtuins contribute to
metabolic regulation, stress responses and various ageing-related
pathologies [4,5]. Of the seven mammalian Sirtuin isoforms, Sirt1
is the closest homologue to the family founding member, yeast
Sir2. Sirt1 is mainly located in the nucleus and deacetylates
various targets, such as histones and transcription factors [6].
Thereby, Sirt1 regulates, e.g., cellular responses to stress factors
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and nutrient availability, and it appears to mediate beneficial
health effects of caloric restriction in higher organisms [3,4].
Sirt1 is thus considered an attractive drug target for metabolic
and ageing-related diseases [7].
Sirtuins are defined by an evolutionarily conserved, ∼250
residue large catalytic domain [1], which comprises a Ross-
mann fold subdomain and a smaller Zn2 + -binding subdomain
[8,9]. The acetyllysine-containing polypeptide substrate occu-
pies a cleft between these two subdomains. The catalytic core
comprises the whole enzyme for some Sirtuins, but is flanked by
N- and C-terminal extensions in other family members [1,10].
For example, an extended N-terminal loop mediates a monomer–
trimer equilibrium of yeast Hst2 in the low to mid micromolar
c© 2013 The Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/
by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.
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range [11], and trimer formation was also suggested for Sirt1
based on SEC (size-exclusion chromatography) [12]. In human
Sirt3, an ∼120 residue N-terminal extension acts as autoin-
hibitory targeting sequence [10,13,14]. Most other human iso-
forms have smaller extensions, mostly of unknown function [2],
whereas Sirt1 has even larger extensions of ∼230 residues at the
N-terminus and ∼220 residues at the C-terminus, respectively.
The Sirt1 N-terminus was reported to mediate recruitment of the
substrate histone H1 [12], similar to Sirt6 recruitment to chro-
matin through its relatively short extensions [15]. Both, N- and
C-terminus, increase Sirt1 catalytic activity, and a short amino
acid stretch within the C-terminal part, which stably associates
with the catalytic core, appears to be of particular importance
for Sirt1 activity [16,17]. A variety of posttranslational modific-
ations in the Sirt1 extensions have been reported, some of them
with a confirmed effect on the enzyme’s activity [18] indicating
a function in dynamic regulation of Sirt1 activity for these re-
gions. Consistently, the N-terminal extension was suggested to
mediate the regulatory interaction with the protein AROS (active
regulator of Sirt1) [19] and pharmacological activation of Sirt1.
Mammalian Sirt1 and its yeast homologue Sir2 can be stimu-
lated in vitro by resveratrol and other STACs (Sirtuin-activating
compounds) [20,21], and their modulation appears to induce be-
neficial health and lifespan effects [22–24]. The Sirt1 N-terminal
extension was reported to be essential for STAC-dependent activ-
ation [20] and resveratrol effects on Sirt1 appear to be substrate
dependent [25,26], but further mechanistic insights are lacking.
Since the compound affects a variety of other proteins [24,27],
insights into its activation mechanism and the development of
improved compounds are urgently required [9].
Here, we study the functions of the N- and C-terminal ex-
tensions in human Sirt1. We test their role in Sirt1 oligomeriz-
ation, revealing that the protein is monomeric in solution and
that its large hydrodynamic radius is likely caused by extended
termini, especially at the N-terminus. We further analyse Sirt1
modulation by several putative Sirt1 regulators, showing that the
regulator protein AROS has an unusual conformation and that
the Sirt1 catalytic domain is sufficient for modulation by res-
veratrol, providing the basis for further mechanistic studies on
Sirt1 regulation.
MATERIALS AND METHODS
Chemicals
All chemicals were obtained from Sigma if not stated differently.
SRT1720 was from Cayman Europe, and peptides were synthes-
ized by GL Biochem.
Cloning, recombinant expression and purification of
human Sirt1 constructs
Full length and deletion constructs of Sirt1 were cloned between
the NdeI and XhoI sites of pET15b vector (Merck) result-
ing in a construct with N-terminal His-tag and a thrombin
protease cleavage site. Sirt1 constructs were expressed in Es-
cherichia coli Rosetta 2 (DE3) cells (Merck) in LB (Luria–
Bertani)/ampicillin/chloramphenicol medium at 37 ◦C until the
A600 had reached 0.5–0.7. Expression was induced with 0.1 mM
IPTG (isopropyl β-D-thiogalactopyranoside), and cells were in-
cubated overnight at 22 ◦C. Cells were harvested by centrifuga-
tion, resuspended in lysis buffer (50 mM Tris, pH 7.5, 300 mM
NaCl and 0.2 mM PMSF) and disrupted using a Microfluidizer
(Microfluidics), and cell debris was removed by 45 min centrifu-
gation at 18 000 rev./min at 4 ◦C in an Avanti J-26XP centrifuge
with a JA-30.50 Ti rotor (Beckman Coulter). The supernatant
was incubated with talon resin (Clontech) for 1 h at 4 ◦C and the
resin was then incubated for 30 min at 4 ◦C with 20 μg/ml (bed
volume) of bovine RNase A and 10 μg/ml of bovine DNase in
25 mM Tris, pH 7.5, 20 mM NaCl, 5 mM MgCl2 and 0.2 mM
PMSF. The column was washed with 20 bed volumes of wash
buffer (lysis buffer containing 10 mM imidazole) followed by elu-
tion with lysis buffer containing 150 mM imidazole. The eluted
protein was concentrated and applied to a pre-equilibrated Super-
dex200 16/60 SEC column (GE Healthcare) and eluted in buffer
A [25 mM HEPES, pH 7.5, 100 mM KCl, 2 mM DTT (dithio-
threitol), 0.1 mM PMSF and 0.5 mM EDTA]. The protein was
bound to a HiTrapQ anion exchange column (GE Healthcare)
in buffer A and eluted in a gradient to buffer A supplemented
with 400 mM KCl. Fractions were analysed by SDS/PAGE, and
Sirt1 fractions were pooled and transferred into storage buffer
(25 mM HEPES, pH 7.5, 100 mM KCl and 2 mM DTT) using a
NAP column (GE Healthcare), aliquoted, snap-frozen in liquid
nitrogen and stored at − 80 ◦C.
SEC
Analytical SEC runs of Sirt1 constructs were performed on a Su-
perose 12 10/300 GL column (24 ml bed volume; GE Healthcare)
pre-equilibrated in Sirt1 storage buffer. Size exclusion standards
were purchased from Biorad and diluted in storage buffer before
applying to the Superose 12 column.
Analytical ultracentrifugation
Experiments were carried out in a Beckman-Coulter XL-A ana-
lytical ultracentrifuge in 25 mM Hepes, pH 7.5, 0.1 M KCl and
0.5 mM DTT using an An-50 Ti rotor. Concentration profiles
were measured at 280 or 230 nm depending on protein concen-
tration using the UV/Vis scanning optics of the centrifuge. SV
(sedimentation velocity) experiments were performed at a ro-
tor speed of 40 000 rev./min at 20 ◦C using standard 3 or 12 mm
centrepieces filled with 100 or 400 μl sample, respectively. The
program package SEDFIT [28] was used for converting measured
concentration profiles into diffusion-corrected differential sedi-
mentation coefficient [c(s)] distributions and for determination
of the molecular mass from diffusion broadening of the sedi-
menting boundary. Buffer density and viscosity and partial spe-
cific volumes of the proteins were determined with the program
SEDNTERP [29] and used for correcting experimental sediment-
ation coefficients to s20,w. For non-associating systems, when a
decrease of the sedimentation coefficient with increasing pro-
tein concentration c was observed, s20,w was corrected by linear
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extrapolation to c = 0 [30]. Sedimentation equilibrium experi-
ments were conducted at 4 ◦C and rotor speeds of 6000, 9000,
12000 and 18 000 rev./min as described previously [31], determ-
ination of molar mass was performed using a model of a single
species [32]. Protein concentrations were determined spectropho-
tometrically using absorption coefficients at 280 nm calculated
from amino acid composition [33].
EM (electron microscopy)
Purified Sirt1 was diluted as required in buffer (20 mM Tris/HCl,
pH 7.8, 150 mM NaCl and 2 mM DTT) and adsorbed for 1 min to
glow-discharged carbon-coated grids. The grids were washed and
negatively stained with 0.07 % uranyl formate (SPI Supplies)
and imaged with a Jeol JEM1400 operated at 120 kV. Electron
micrographs were recorded at a magnification of ×50000 on
Kodak SO-163 films.
CD spectra
Protein samples were diluted in 2.5 mM HEPES, pH 7.5, 10 mM
KCl and 0.2 mM DTT to a concentration of 9.5 μM (full-
length Sirt1) or 10 μM (AROS), respectively. CD spectra were
then measured at 15 ◦C using a Jasco J600A CD spectrophoto-
meter. Spectra were recorded in continuous scanning mode at
100 nm/min between 260 nm and 180 nm with 1 nm bandwidth,
an accumulation of eight scans per spectrum and a response time
of 1 s, and they were baseline corrected using the corresponding
buffer spectrum.
Peptide deacetylation assays
Deacetylase activity of Sirt1 against the fluorogenic, p53-derived
FdL-1 (Fluor-de-Lys-1) peptide RHK-acetylK-fluorophor was
tested with a commercial Sirt1 assay kit (Enzo Life Sciences).
Reactions were incubated at 37 ◦C with 0.5 μg Sirt1, 25 μM
fluorogenic peptide and 0.25 mM NAD+ . Detection of a reac-
tion product was performed according to the instructions of the
manufacturer. For assays with a non-fluorogenic, non-modified
substrate peptide, deacetylation of 100 μM of a p53-derived pep-
tide (RHK-acetylK-LMFK) was monitored in a coupled, con-
tinuous enzymatic assay at 25 ◦C and 1 mM NAD+ as described
before [34,35]. In control reactions and blanks, the same amount
of solvent used for its stock solution or compound analysed,
respectively, was included. All assays were done in triplicate,
and results shown are representatives of at least two independent
replications.
Homology modelling
The catalytic core of human Sirt1 was homology modelled using
the Phyre2 [36] server at http://www.sbg.bio.ic.ac.uk/phyre2.
RESULTS
Apparent size of Sirt1 and Sirt1 deletion constructs
Sirt1 was suggested to form trimers [12], while Sirtuin cata-
lytic domains are mainly monomeric (see the Discussion sec-
tion), and protein oligomerization often contributes to regula-
tion [37]. To analyse a potential regulatory function of trimer
formation and the role of the N- and C-terminal extensions
in Sirt1 oligomerization and regulation, we recombinantly pro-
duced full-length protein and deletion variants of human Sirt1
(Figure 1A). The apparent molecular masses were then ana-
lysed through SEC (Figure 1B) and compared with molecular
mass standards (Figure 1C). This analysis indicated a size of
∼230 kDa for full-length Sirt1, which would fit well to a tri-
mer of the 84 kDa protein, consistent with the apparent forma-
tion of trimers detected by SEC, as reported before [12]. Trun-
cation of the C-terminal region (Sirt1-1-664, calculated mass
75 kDa) resulted in elution comparable with a ∼150 kDa pro-
tein, close to an apparent dimer, whereas truncation of the N-
terminus (Sirt1-214-747, calculated mass 62 kDa) resulted in
elution like a 90 kDa protein, between the monomer and di-
mer mass. Removing both extensions (Sirt1-214-664 and Sirt1-
225-665, calculated masses 53 and 52 kDa, respectively) gave
proteins eluting comparable with 70–80 kDa proteins, again a
mass between monomer and dimer. A construct completely re-
duced to the catalytic core, Sirt1-229-516, eluted as expected for
the 33 kDa monomer. SEC elution volumes depend not only
on the molecular mass but also on the protein’s shape [38], with
deviation from spherical shape resulting in lower elution volumes
corresponding to higher apparent molecular masses. An elution
volume expected for a spherical monomer was observed for Sirt1
only when both terminal extensions were removed, indicating that
its termini either mediate oligomerizations or cause an elongated,
non-spherical shape.
Sirt1 is a monomeric protein with disordered
regions or elongated shape
The observed SEC behaviour could be due to Sirt1 homo-
oligomerization or be caused by an extended shape of the protein.
To characterize its molecular shape, we negatively stained the
full-length Sirt1 protein and analysed it by EM (Figure 1D). We
observed small homogenous particles of spherical to elongated
shape indicating that Sirt1 is indeed a monomer with a thin and
elongated or largely disordered part.
To clarify whether full-length Sirt1 forms oligomers in solu-
tion, we analysed Sirt1 in SV experiments in the analytical ul-
tracentrifuge in a concentration range from 0.8 to 40 μM. Cal-
culation of c(s) distributions revealed that the main species of
full-length Sirt1, which comprises approximately 80 % of the
total signal, sedimented with an s20,w of 4.0 S (Figure 1E). If
this species were trimeric Sirt1, a frictional ratio of 3.7 would
be obtained when compared with a spherical, unhydrated trimer.
This value is much higher than expected for an at least partially
folded protein [39]. Analysis of the diffusion broadening of the
sedimenting boundary yielded a molecular mass of 76 kDa for
the main Sirt1 full-length species. Since the calculated monomer
mass is 83.9 kDa, full-length Sirt1 predominantly exists as a
monomer in solution. A frictional ratio of 1.8 can be calculated
from s20,W for this monomer. Since a frictional ratio of 1.1–1.2
would be expected for a hydrated, spherical protein [40], the
Sirt1 behaviour deviates substantially from that of a sphere, most
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Figure 1 Overall architecture of human Sirt1
(A) Schematic view of full-length human Sirt1 with tentative borders indicated for the conserved Sirtuin catalytic domain.
The Sirt1 deletion constructs used in our studies, which lack N- and/or C-terminal extensions to the catalytic core, are
indicated. (B) Elution profiles of full-length human Sirt1 and Sirt1 deletion constructs in SEC experiments. (C) Comparison
of the elution volumes of Sirt1 constructs to a molecular mass marker. For all constructs, the calculated sizes of a
monomer, dimer and trimer are indicated at the respective elution volume. (D) EM image of negatively stained human
Sirt1, showing defined, monomeric particles with a small, roughly spherical core. Scale bar, 40 nm. (E) SV analysis of
0.8 μM full-length Sirt1 monitored at 230 nm (black) and of 6.5 μM (green), 20 μM (blue) and 40 μM (red) full-length
Sirt1 monitored at 280 nm. For better comparison all c(s) distributions have been converted to 12 mm path length. (F)
Sedimentation equilibrium analysis of 6.5 μM full-length Sirt1. Concentration gradients were measured at 280 nm and
6000 rev./min (red), 9000 rev./min (blue), 12 000 rev./min (green) and 18 000 rev./min (black) with path length 12 mm.
Global fitting using a single species model yielded a molecular mass of 93 kDa (solid curves). The lower panel represents
differences between calculated and measured values. (G) SV analysis of N-terminally shortened variants Sirt1-214-747
(red) and Sirt1-214-664 (black) at 1.2 μM (solid lines, 230 nm) and 25 μM or 30 μM (broken lines, 280 nm), respectively.
(H) CD spectrum of full-length human Sirt1. (I) Scheme for the architecture of human Sirt1: a conserved Sirtuin catalytic
core (shown as a homology model) is flanked by a largely disordered N-terminal extension (right, dark grey) and a C-terminal
region folded back on to the catalytic core (left, red) via an extended or disordered linker, possibly followed by a smaller
disordered region (light grey).
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probably due to disordered regions and/or a highly elongated
shape. The high frictional ratio of full-length Sirt1 is likely
the reason why SEC analysis yielded an apparent molecular
mass much higher than expected for a monomer. Comparison
of c(s) distributions at different protein concentrations revealed
that the s-value of the main species slightly decreases with in-
creasing protein concentration (Figure 1E), which is typical for
non-associating systems, especially if the protein shows some
asymmetry [30]. The fraction of species in c(s) distributions with
s-values higher than the main peak did not increase when increas-
ing the protein concentration 50-fold (Figure 1E), indicating that
these species represent impurities rather than higher oligomers
of Sirt1. We performed further sedimentation equilibrium exper-
iments with full-length Sirt1, which were analysed with a model
of a single species and yielded a molecular mass of 93 kDa (Fig-
ure 1F). This value is in good agreement with the monomeric
Sirt1 mass (83.9 kDa), with the slight deviation most probably
being caused by the faster sedimenting impurities observed in SV
analysis. We thus conclude that full-length Sirt1 is monomeric in
solution and that its shape is non-spherical, likely due to disorder
or an extended shape.
SV analysis of the C-terminally truncated Sirt1 construct
Sirt1-1-664 in a concentration range from 0.9 to 39 μM yiel-
ded very similar results to the full-length protein (Supplement-
ary Figure S1A available at http://www.bioscirep.org/bsr/033/
bsr033e037add.htm). The s20,w-value of the main species was
slightly reduced to 3.9 S and the frictional ratio, relative to an
unhydrated, spherical monomer slightly decreased to 1.7. The C-
terminal region thus contributes only slightly to Sirt1 asymmetry.
From c(s) analysis a molecular mass of approximately 71 kDa
was obtained (calculated mass 75.1 kDa) and a sedimentation
equilibrium experiment analysed with a model of a single species
yielded a molecular mass of 79 kDa (Supplementary Figure S1B).
We therefore conclude that the C-terminally truncated version
Sirt1-1-664, like the full-length protein, predominantly forms an
elongated or partly unstructured monomer in solution. The N-
terminally truncated proteins Sirt1-214-747 and Sirt1-214-664,
however, showed a different behaviour. In c(s) distributions sev-
eral peaks were visible and the weight average c(s) increased with
increasing protein concentration (Figure 1G). This result indic-
ates that the N-terminally truncated forms of Sirt1 can undergo a
concentration-dependent oligomerization [41] and resembles the
observations for yeast Hst2 [11]. An explanation for the differ-
ent behaviour of N-terminally truncated Sirt1 compared with the
full-length enzyme could be an interference of the highly negat-
ively charged patches in the N-terminus with oligomer formation
of full-length Sirt1. Such a scenario could have physiological rel-
evance as a regulation mechanism for Sirt1 oligomerization, e.g.,
by interaction partners binding the Sirt1 N-terminus and relieving
its shielding effect. However, the observation that N-terminally
truncated Sirt1 forms a variety of different oligomeric species
and that oligomer amounts are significant only at higher micro-
molar concentrations, which likely exceed physiological Sirt1
concentrations, strongly suggest that this oligomerization is non-
physiological. Taken together, our results suggest that Sirt1 is
monomeric in solution, and that its shape deviates from a sphere
due to disorder or an extended shape especially in its N-terminal
extension.
In order to determine the secondary structure content of Sirt1
and thereby to distinguish between disorder and an elongated
shape for its extensions, we recorded a CD spectrum of the
full-length protein (Figure 1H). The spectrum shows typical fea-
tures for a protein with repetitive secondary structure, with a
prominent minimum at 222 nm. However, the signal intensity is
weak for an 82 kDa protein, and fitting the spectrum with ref-
erence spectra [42] indeed indicated only ∼11 % α-helical and
∼23 % β-sheet structure. Since sequence homology strongly in-
dicates the generic Sirtuin catalytic core structure for the central
part of Sirt1, we conclude that large parts of the N- and/or C-
terminal Sirt1 extensions have no regular secondary structure or
are disordered. Consistently, statistical analysis of the Sirt1 se-
quence using DisEMBL [43] indicates a disordered region cov-
ering, with small exceptions, altogether ∼35 residues, the Sirt1
N-terminus up to position 175 (Supplementary Figure S2A avail-
able at http://www.bioscirep.org/bsr/033/bsr033e037add.htm). A
mixture of ordered and disordered regions is predicted C-terminal
from residue 530, after the ordered catalytic core. Analogous ana-
lysis using GlobPlot [44] resulted in comparable predictions, with
disordered regions from 1 to 180 and 660 to 747 (Supplementary
Figure S2B). Integrating with our results the recent finding that an
∼20 residue stretch around position 640 appears to interact with
and activate the catalytic core [17] indicates the following Sirt1
architecture (Figure 1I): a compact catalytic domain, which can
be modelled reliably due to its homology to structurally charac-
terized Sirtuins, has a C-terminal extension of a defined structure
that folds back, via an extended or disordered linker, on the cata-
lytic domain for activity regulation. The complete N-terminal
extension, in contrast, is largely disordered in the absence of an
interaction partner.
Testing Sirt1 regulation through AROS
Besides oligomerization, additional Sirt1-specific features sup-
posedly mediated by the N- and C-terminal extensions have been
reported, such as regulation by resveratrol (see below), phos-
phorylation (see [18] for a review), and regulation by the pro-
teins AROS and DBC1 (deleted in breast cancer 1) [19,45]. To
test the role of the Sirt1 N-terminus as an AROS binding site
(residues 114-217 [19]), which we speculated could stabilize this
region and thus enable its structural characterization, we gener-
ated recombinant AROS protein with an N-terminal His-tag. The
protein was efficiently overexpressed but insoluble. We therefore
established a refolding protocol that yielded pure protein eluting
as a single peak in SEC with an apparent molecular mass corres-
ponding to a monomer (Figure 2A), indicating that the protein
was folded in a globular shape. To test whether the protein has
a defined structure, we analysed its secondary structure through
CD spectroscopy. The AROS CD spectrum (Figure 2B) indeed
shows a deviation from random conformation, yet partially an
unusual protein secondary structure. The spectrum can be fitted
with a combination of reference spectra [42] beyond 210 nm, in-
dicating ∼33 % α-helical and ∼12 % β-sheet structure. The deep
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Figure 2 Characterization of the Sirt1 activator protein AROS
(A) Refolding overexpressed AROS resulted in pure protein, judged based on SDS/PAGE (inset), eluting in SEC experiments
in the volume expected for a spherical monomer. (B) CD spectrum of refolded AROS protein, featuring minima at 222 nm
and 203 nm. (C) FdL-based assay on Sirt1 activity in the presence and absence of AROS protein. Even a 10-fold molar
excess of AROS protein did not result in a statistically significant change in Sirt1 activity.
minimum at 203 nm and steep increase below 200 nm, however,
does not fit typical spectra of α-helix, β-sheet and random con-
formations. However, this minimum closely resembles spectra
of poly(Pro) conformations [46]. The CD spectrum thus sug-
gests not only a folded AROS protein featuring regions in α-
helix and β-sheet conformation but also a significant part with
poly(Pro) conformation. Adding the recombinant AROS protein
to aminomethylcoumarin-peptide based FdL assays [47] on Sirt1
deacetylation activity resulted in a very weak inhibitory effect,
which was not statistically significant (Figure 2C), but an ac-
tivating effect in these assays can be ruled out. However, we
cannot exclude the possibility that our AROS protein is partially
not folded, since no functional test is available and no natively
purified AROS for comparison, although our data strongly sug-
gest proper folding. Furthermore, the recombinant AROS might
lack cofactors or further interacting proteins required for binding
and/or regulating Sirt1.
The N-terminal Sirt1 domain is dispensable for
modulation by resveratrol
The Sirt1-specific N-terminal domain was reported to be essen-
tial for the enzyme’s activation by resveratrol [20], but other
reports showed resveratrol-dependent activation also for mam-
malian Sirt5 [48] and yeast Sir2 [21], which have N-terminal
domains unrelated to Sirt1. We therefore tested resveratrol ef-
fects on our Sirt1 constructs covering the catalytic domain with
or without the N- and C-terminal extensions to identify the Sirt1
parts required for stimulation. Although the fluorophor of the FdL
substrate was shown to influence activation, resveratrol effects
have also been observed with non-modified substrates [48,49]
and a better understanding of this mechanism is urgently needed
[9]. For our tests on the domains involved we thus used the FdL as-
say, despite the non-physiological nature of the substrate, to keep
our tests as comparable as possible to the previous study. The
Sirt1 deletion constructs showed a significant reduction in basal
activity (Figure 3A), consistent with previous reports [16,17].
However, resveratrol stimulated all constructs, and comparing
stimulated activities to the respective basal activity in fact indic-
ates that the strength of the stimulatory effect varies only slightly
between constructs (Figure 3B). Even a minimal construct of the
Sirt1 catalytic core (residues 229–516) was significantly activ-
ated, although the stimulatory effect was approximately 2-fold
smaller than for full-length Sirt1. We further tested the effect
of piceatannol, a resveratrol-related compound also reported to
activate Sirt1 [21]. As for resveratrol, comparable relative in-
creases of basal activity were observed for all constructs tested
(Figure 3C). We thus conclude that resveratrol-dependent activ-
ation requires only the catalytic core of Sirt1, whereas its unique
N-terminal domain is not necessary for the effect.
A regulatory mechanism reported for the Sirt1 C-terminus is
to act as a modification site for regulatory phosphorylations [18].
We indeed find that a Sirt1 mutation mimicking phosphorylation
at residue 530 (T530D), immediately C-terminal to the cata-
lytic core, increases basal activity (Figure 3D), consistent with
a previous report [50]. Using the T530D variant, we then tested
whether Sirt1 activation through Thr530 phosphorylation and by
resveratrol exploit a common mechanism, such as a shared dock-
ing site or conformational change, or whether they are additive.
Comparison of Sirt1-T530D activity in the presence and absence
of resveratrol clearly showed a stimulatory effect of the com-
pound (Figure 3E). We thus conclude that the regulatory Sirt1
phosphorylation at Thr530 and stimulation by resveratrol exploit
two independent Sirt1 regulation mechanisms.
Testing Sirt1 modulation by cAMP, cGMP and
SRT1720
Resveratrol was recently reported to be a competitive inhib-
itor of several PDEs (phosphodiesterases) [51], showing that the
compound can occupy binding sites for the cyclic nucleotides,
cAMP and cGMP. We thus speculated that the other way round,
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Figure 3 Regulation of Sirt1 activity by small molecules
(A) Deacetylation activity of full-length Sirt1 and Sirt1 deletion constructs in the FdL assay. (B) Activation of Sirt1 and Sirt1
deletion constructs in the FdL assay by 100 μM resveratrol (RESV) shows only a weak decrease in the relative stimulation
for shortened constructs. (C) Activity in FdL assays of full length Sirt1 and deletion constructs in the presence of 100 μM
of the resveratrol-related compound piceatannol (PCT), relative to their basal activity. (D) FdL activity of the phosphorylation
mimicking variant Sirt1-T530D compared with the activity of the same amount of wild-type (wt) enzyme. (E) Comparison
of basal and resveratrol (RESV)-stimulated (100 μM) FdL activity of full-length human Sirt1-wt and Sirt1-T530D. (F) FdL
deacetylation activity of full-length Sirt1 in the presence (100 μM) and the absence of the cyclic nucleotides cAMP and
cGMP. The same set of experiments was done in the absence (left) and in the presence (right) of 100 μM resveratrol. The
activity in the absence of any ligands was used as reference and set to 100 %. (G) Effects of SRT1720 (1 μM) on the
Sirt1-dependent deacetylation of FdL-peptide and of a p53-derived non-modified peptide.
cAMP/cGMP could be physiological ligands for the resveratrol-
binding site of Sirt1. However, testing Sirt1 alone and in the
presence of cAMP or cGMP, respectively, yielded no signific-
ant changes in Sirt1 activity (Figure 3F), indicating that these
cyclic nucleotides do not regulate Sirt1. Furthermore, adding
cAMP or cGMP in the presence of resveratrol did not influence
resveratrol-dependent Sirt1 activation, showing that the cyclic
nucleotides do not bind to the Sirt1 site that mediates activation by
resveratrol.
SRT1720 is a resveratrol-unrelated small molecule that stim-
ulates Sirt1-dependent deacetylation of a substrate peptide [20],
has resveratrol-like physiological effects [7,52] and was specu-
lated to act as a PDE inhibitor [51]. In contrast with the previously
reported activating effect in assays on an extended peptide, we
find that SRT1720 has a weak inhibitory effect on Sirt1 in the
FdL assay and against a non-modified p53 peptide (in a coupled
enzymatic assay; Figure 3G), consistent with a previous study
[53]. These different effects on Sirt1 activity against different
substrates, as observed for resveratrol (see the Discussion sec-
tion), might indicate the exciting possibility to develop substrate-
specific modulators for Sirt1.
DISCUSSION
Sirt1 regulates central cellular processes and constitutes an at-
tractive drug target for metabolic and ageing-related diseases
[4,7]. However, its domain architecture and regulation are little
understood on a molecular level. Sirt1 was suggested to form
homo-trimers based on SEC experiments [12], and a monomer–
trimer equilibrium mediated by N- and C-terminal extensions
was observed for the yeast Sirtuin Hst2 [11]. Since Sirtuin cata-
lytic domains have been described as monomers [8,54], the Sirt1
termini might mediate oligomerization. Our experiments show,
however, that Sirt1 is a monomer that migrates fast in SEC due
to an extended conformation, apparently mainly due to a dis-
ordered N-terminus, consistent with bioinformatics analyses re-
ported here and previously [55]. The C-terminus also appears to
harbour disordered regions, but partially seems to adopt a defined
conformation that interacts with the catalytic core [17]. In fact,
both termini increase the low activity of the catalytic core (our
data and [16]), and we speculate two mechanisms could be in-
volved: they might increase the stability of the catalytic core,
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which would be consistent with the low long-term stability we
observed especially for short Sirt1 constructs, and they seem to
mediate dedicated regulation mechanisms. Consistent with the
latter idea, the Sirt3 N-terminus was also found to influence
catalytic core activity [13,14], several regulatory phosphoryla-
tion sites are known in the Sirt1 termini [18], and the binding
site for the Sirt1 activator AROS was located to the N-terminal
domain [19]. In fact, the large apparent size of Sirt1 from nat-
ural sources can be explained by its disordered termini, but could
also be caused by formation of larger complexes through inter-
actions of the termini, similar to the recruitment of the substrate
histone H1 through the N-terminus of Sirt6 [12]. Interestingly,
full-length Sirt2 from natural sources also behaves like a trimer
in SEC [56], which could indicate an extended conformation of
the Sirt2 C-terminus (∼120 residues) and/or formation of larger
complexes. Bioinformatics analyses indeed indicate a high prob-
ability for disorder and coiled-coil formation in the ∼60 Sirt2 C-
terminal residues (Supplementary Figures S3A and S3B available
at http://www.bioscirep.org/bsr/033/bsr033e037add.htm), which
thus might be structurally related to the disordered/extended Sirt1
N-terminus despite a lack of significant sequence homology. In-
terestingly, for affinity purified recombinant Sirt1, a high absorp-
tion at 260 nm and treatment with DNase/RNase indicated that
RNA is copurified (Supplementary Figures S4A and S4B avail-
able at http://www.bioscirep.org/bsr/033/bsr033e037add.htm).
However, we could neither detect nucleic acid binding nor ef-
fects of nucleic acids on Sirt1 activity (results not shown). Since
nucleic acids might also bind to the metal ions used for affinity
purification, a nucleic acid-binding function for Sirt1 remains
speculative.
For Sirt1 activation by resveratrol and other STACS, the N-
terminus was reported to be essential, in particular residues 183–
225 [20]. Depending on the substrate used, also Sirtuin inhibition
has been observed in the presence of resveratrol [48,49], but a
similar mechanism as for activation has to be assumed since no
available evidence suggests otherwise. In contrast with the pre-
vious study on Sirt1 domains involved [20], we find that the
entire N- and C-terminal Sirt1 extensions are dispensable for ac-
tivation, which in fact is supported by data shown in [20] that
activation is reduced but still detectable for the catalytic core.
Since both termini also increase catalytic core activity (our work
and [16]), shorter constructs yield lower absolute activities even
when stimulated, which might have led to a misinterpretation that
no significant stimulation occurs. However, we conclude that the
N-terminus might indirectly affect resveratrol-dependent activa-
tion through its effect on catalytic core stability and/or activity,
but the catalytic core contains all elements essential for stim-
ulation by resveratrol. This activation mechanism thus appears
to differ from activation by AROS, which binds to the Sirt1 N-
terminus [19]. Since the catalytic core is evolutionarily conserved
in all Sirtuins, it is tempting to speculate that small molecule
activators might also exist for other family members, such as
other mammalian Sirtuin isoforms. In fact, compounds activat-
ing non-specifically Sirt1, 2 and 3 were described [57], and the
resveratrol-related compound piceatannol was shown to inhibit
Sirt2 [58] and affect Sirt5 depending on the substrate used [48].
Interestingly, the activating effect of Sirt1-Thr530 phosphoryla-
tion is substrate-dependent and resveratrol can either activate
or inhibit Sirt1 depending on the substrate used [25,49], which
might indicate that resveratrol-like compounds could stimulate
other Sirtuins if tested with the appropriate substrate. In fact, our
failure to observe Sirt1 activation by AROS could also be due to
a substrate-dependent effect. These substrate-dependent effects
might indicate either a direct interaction between Sirt1-bound
substrate and compound/modification, or an allosteric interaction
between both sites, but further structural studies will be needed
for fully understanding the modulation mechanism. Our results
show that for such studies, the N- and C-terminal extensions of
Sirt1 can be neglected, and thus provide the basis for further
mechanistic studies on Sirt1 regulation.
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Figure S1 Analytical ultracentrifugation analysis of Sirt1-1-664
(A) SV analysis. c(s) distributions of Sirt1-1-664 obtained from sedimentation profiles at 0.9 μM monitored at 230 nm
(black), or 280 nm and 7.0 μM (green), 20 μM (blue) and 39 μM (red). For better comparison all c(s) distributions
have been converted into 12 mm path length. (B) Sedimentation equilibrium analysis. The concentration gradients for
28 μM Sirt1-1-664 were measured at 280 nm and 6000 rev./min (red), 9000 rev./min (blue), 12 000 rev./min (green)
and 18 000 rev./min (black) with a path length of 3 mm. Global fitting using a model of a single species yielded a
molecular mass of 79 kDa (solid curves). The lower panel represents the difference between calculated and measured
values (residuals).
1 Present address: Stowers Institute for Medical Research, Kansas City, MO, U.S.A.
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Figure S2 Analysis of the protein sequence of human Sirt1
(A) DisEMBL scores for the amino acid sequence of human Sirt1, indicating large potentially disordered regions at the
N- and C-terminus, respectively. (B) GlobPLOT analysis of the human Sirt1 protein sequence, again indicating potentially
disordered regions at the N- and C-terminus.
Figure S3 Analysis of the protein sequence of human Sirt2
(A) DisEMBL scores for the amino acid sequence of human Sirt2 indicating potentially disordered regions, in particular
a ∼40 residue stretch at the C-terminus. (B) COILS analysis of the human Sirt2 protein sequence, indicating a potential
coiled-coil region preceding the flexible C-terminus.
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Architecture and regulation of human Sirt1
Figure S4 Sirt1 appears to co-purify with polynucleotides
(A) UV/vis-spectroscopic analysis of different fractions of affinity purified Sirt1 shows a high A260/A280 ratio for an
untreated control sample, whereas samples treated with nucleases, while bound on the affinity column show a decrease
in the ratio (A260/A280 ratios: control ∼1.08, treated with DNase: ∼1.06, treated with RNase: ∼0.68, treated with
DNase + RNase: ∼0.70). (B) Agarose gel (1 % w/v) electrophoresis of Sirt1 shows a nucleic acid content that can be
removed through incubation with bovine DNase (moderate decrease) or bovine RNase A (complete loss). Sirt1 was also
incubated with Subtilisin to investigate if loss of Sirt1 leads to a shift in the migration of nucleic acids, but no effect was
visible. Approximately 6.25 μg of Sirt1 was incubated with 0.625 ng of Subtilisin, 0.25 μg of DNase, or 0.5 μg of RNase,
respectively, for 15 min at 37 ◦C before loading on the gel.
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